Watson Hopes Accelerated Approval For Progesterone Gel Remains Option
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Company will meet with FDA to determine a path forward now that the agency has issued a “complete response” letter for progesterone vaginal gel 8% for reducing the risk of preterm birth in women with a short cervix, Watson CEO Bisaro says.